Downward price movements and volatility in Lineage Cell Therapeutics stock are typically driven by broader macroeconomic risk-off sentiment hitting pre-revenue biotech sectors, periodic cash-burn disclosures, and the inherent uncertainty of clinical trial timelines. Because clinical-stage firms rely heavily on secondary equity offerings to fund research, market sentiment shifts regarding dilution can trigger short-term selling pressure.